Author

H.S. Lu

Observed name: H. Lu

Institutions: Chongqing University, Shandong Tumor Hospital, Second Hospital of Yichang, Chongqing Cancer Hospital, Shandong First Medical University, Wake Forest University Health Sciences, Wake Forest University

Observed institutions: Chongqing University, Shandong Tumor Hospital, Second Hospital of Yichang, Chongqing Cancer Hospital, Shandong First Medical University, Wake Forest University Health Sciences, Wake Forest University

OpenAlex ID: A5152878480

Efficacy and Prognosis of Neoadjuvant Chemoimmunotherapy Followed by Concurrent Chemoradiotherapy in Unresectable Esophageal Cancer: The First Single-Center Real-World Study

2026 · X. Zhang, W. Zhao, et al. · International Journal of Radiation Oncology*Biology*Physics

Validation of a Multi-Omic Biosignature in a Multi-Institutional Cohort to Predict Locoregional Recurrence Risk and Differential RT Effect in Early-Stage Invasive Breast Cancer

2026 · A.J. Khan, G.B. Mann, et al. · International Journal of Radiation Oncology*Biology*Physics

Early Mortality after Thoracic Radiotherapy for Lung Cancer: Identifying a High-Risk Subgroup through Initial Radiation Pneumonitis Severity

2026 · H. Lu, Q. Lei, et al. · International Journal of Radiation Oncology*Biology*Physics

Tislelizumab Combined with Chemotherapy Followed by Consolidative Thoracic Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

2026 · W. Zhou, J. Guo, et al. · International Journal of Radiation Oncology*Biology*Physics

Time of Day Radiotherapy and Radiation Pneumonitis in Lung Cancer with Interstitial Lung Disease

2026 · H. Lu, A. Jiang, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 5

Citation count:

H-index:

I10-index: